Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes
UC expert comments on study to NBC News
The University of Cincinnati's Alberto Espay, MD, commented to NBC News on new research published Oct. 24 that found semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes.
The new study compared semaglutide to seven other diabetes drugs, including metformin, insulin and older GLP-1 drugs, including liraglutide.
Researchers found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The results were consistent across gender, age and weight.
Espay, who was not involved in the study, told NBC News more research is needed to determine if the drugs actually work against Alzheimer's. He noted previous early research showed similar positive effects for people who took drugs including statins or insulin, but none of those potential treatments panned out.
“Just as with statins, NSAIDs and insulin, we should be cautious about claiming semaglutide can treat or prevent Alzheimer’s based on this study alone,” Espay said.
Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.
Related Stories
These teeny spiders are social media stars
August 28, 2026
The New York Times turned to a University of Cincinnati professor to explain the appeal of jumping spiders on social media.
An internal divide among unions on AI impacts the Wisconsin gubernatorial race
August 28, 2026
Anne Lofaso, a professor in the Donald P. Klekamp College of Law at UC, spoke with Wisconsin Public Radio, about the schism among unions over AI and whether it is a plus, a negative, or somewhere in between when looking at job creation.
On-site training in Speech & Hearing Clinic sets UC’s programs apart
August 27, 2026
At the University of Cincinnati’s Speech & Hearing Clinic, Doctor of Audiology and Speech-Language Pathology graduate students gain real-world experience while providing free speech and hearing services to the community.